Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results
![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f51f7be2a785a634b19beb625ffd9628c0abfdfa-1920x1080.png?fit=crop&auto=format)
February 26th 2024
Article
A phase 1/2 study found that using azacitidine, venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia yielded high rates of complete response and complete response with incomplete hematologic recovery.